Table 2

Incidence of diabetes for the patients with rheumatoid arthritis according to use of cDMARDs and bDMARDs

Column vs row: aHR (95% CI)*
Treatment exposureTotal person-yearIncidence (95% CI)†Any bDMARDsMTX combinationOther cDMARDsNon-DMARDs
MTX monotherapy1536.619.5 (12.5 to 26.5)0.51 (0.32 to 0.83)‡0.50 (0.32 to 0.78)‡0.56 (0.37 to 0.84)‡1.03 (0.68 to 1.57)
Any bDMARDs4047.09.1 (6.2 to 12.1)0.98 (0.65 to 1.46)1.08 (0.75 to 1.57)2.01 (1.38 to 2.94)‡
MTX combination6846.89.6 (7.3 to 12.0)1.11 (0.82 to 1.50)2.07 (1.50 to 2.84)‡
Other cDMARDs11 037.812.2 (10.2 to 14.3)1.86 (1.43 to 2.42)‡
Non-DMARDs22 869.411.7 (10.3 to 13.1)
  • *Models were adjusted for age, sex, body mass index grouping (the patients with missing data were one of the groups), smoking, alcohol drinking, hypertension, hyperlipidaemia, gout, chronic kidney disease, hepatitis B virus infection, hepatitis C virus infection, coronary arterial disease, stroke, and time-dependent use of statins and steroids.

  • †Expressed as number of events per 1000 person-years.

  • ‡P<0.05.

  • aHR, adjusted HR; bDMARDs, biological disease-modifying anti-rheumatic drugs; cDMARDs, conventional disease-modifying anti-rheumatic drugs; MTX, methotrexate.